Successful treatment of stage III neuroblastoma based on prospective biologic staging: A Children's Cancer Group study

Journal of Clinical Oncology

Volumn 16, Issue 4, 1998, Pages 1256-1264

  Matthay, Katherine K ^a   Perez, Carlos ^b   Seeger, Robert C ^b   Brodeur, Garrett M ^b   Shimada, Hiroyuki ^b   Atkinson, James B ^b   Black, C Thomas ^b   Gerbing, Robert ^b   Haase, Gerald M ^b   Stram, Daniel O ^b   Swift, Patrick ^b   Lukens, John N ^b  

^a CHILDREN S ONCOLOGY GROUP   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MESNA; RETINOIC ACID;

ADOLESCENT; ADVANCED CANCER; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER STAGING; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; DRUG EFFECT; FEMALE; GENETIC HETEROGENEITY; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROBLASTOMA; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

EID: 0031901264     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.4.1256     Document Type: Article

References (26)

1. Evans AR, Brand W, de Lorimier A, et al: Results in children with local and regional neuroblastoma managed with and without vincristine, cyclophosphamide, and imidazolecarboxamide. A report from the Children's Cancer Study Group. Am J Clin Oncol 6:3-8, 1984
2. Ikeda K, Nakagawara A, Yano H, et al: Improved survival rates in children over 1 year of age with stage III or IV neuroblastoma following an intensive chemotherapeutic regimen. J Pediatr Surg 24:189-193, 1989
3. Castleberry RP, Kun LE, Shuster JJ, et al: Radiotherapy improves the outlook for patients older than 1 year with Pediatric Oncology Group stage C neuroblastoma. J Clin Oncol 9:789-795, 1991
4. Garaventa A, De Bernardi B, Pianca C, et al: Localized but unresectable neuroblastoma: Treatment and outcome of 145 cases. J Clin Oncol 11:1770-1779, 1993
5. West DC, Shamberger RC, Macklis RM, et al: Stage III neuroblastoma over 1 year of age at diagnosis: Improved survival with intensive multimodality therapy including multiple alkylating agents. J Clin Oncol 11:84-90, 1993
6. Castel V, Badal MD, Bezanilla JL, et al: Treatment of stage III neuroblastoma with emphasis on intensive induction chemotherapy: A report from the Neuroblastoma Group of the Spanish Society of Pediatric Oncology. Med Pediatr Oncol 24:29-35, 1995
7. Haase GM, Atkinson JB, Stram DO, et al: Surgical management and outcome of locoregional neuroblastoma: Comparison of the Childrens Cancer Group and the International staging systems. J Pediatr Surg 30:289-295, 1995
8. Shimada H, Chatten J, Newton WA, et al: Histopathologic prognostic factors in neuroblastic tumors: Definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 73:405-416, 1984
9. Harm HWL, Evans AE, Siegel SE, et al: Prognostic importance of serum ferritin in patients with stages III and IV neuroblastoma: The Childrens Cancer Study Group Experience. Cancer Res 45:2843-2848, 1985
10. Seeger RC, Brodeur GM, Sather H, et al: Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313:1111-1116, 1985
11. Castleberry RP, Shuster JJ, Altshuler G, et al: Infants with neuroblastoma and regional lymph node metastases have a favorable outlook after limited postoperative chemotherapy: A Pediatric Oncology Group Study. J Clin Oncol 10:1299-1304, 1992
12. Rubie H, Hartmann O, Michon J, et al: N-myc gene amplification is a major prognostic factor in localized neuroblastoma: Results of the French NBL 90 study. J Clin Oncol 15:1171-1182, 1997
13. Bowman LC, Castleberry RP, Cantor A, et al: Genetic staging of unresectable or metastatic neuroblastoma in infants: A Pediatric Oncology Group study. J Natl Cancer Inst 89:373-380, 1997
14. Brodeur GM, Seeger RC, Schwab M, et al: Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1121-1124, 1984
15. Seeger RC, Wada R, Brodeur GM, et al: Expression of N-myc by neuroblastomas with one or multiple copies of the oncogene. Prog Clin Biol Res 271:41-49, 1988
16. Chatten J, Shimada H, Sather HN, et al: Prognostic value of histopathology in advanced neuroblastoma: A report from the Childrens Cancer Study Group. Hum Pathol 19:1187-1198, 1988
17. Moss TJ, Reynolds CP, Sather HN, et al: Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. N Engl J Med 324:219-226, 1991
18. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
19. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
20. Brodeur GM, Pritchard J, Berthold F, et al: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466-1477, 1993
21. Matthay KK, Lukens J, Stram D, et al: Prognosis for stage IV neuroblastoma less than one year at diagnosis: A prospective Childrens Cancer Group study. Proc Am Soc Clin Oncol 14:446, 1995. (abstr)
22. Shimada H, Stram DO, Chatten J, et al: Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. J Natl Cancer Inst 87:1470-1476, 1995
23. Stram DO, Matthay KK, O'Leary M, et al: Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: A report of two concurrent Children's Cancer Group Studies. J Clin Oncol 14:2417-2426, 1996
24. Matthay KK, Stram D, Seeger RC, et al: A prospective Childrens Cancer Group study of stage II neuroblastoma treated with surgery alone. Proc Am Soc Clin Oncol 12:414, 1993 (abstr)
25. Haase GM, O'Leary MC, Stram DO, et al: Pelvic neuroblastoma - Implications for a new favorable subgroup: A Children's Cancer Group Experience. Ann Surg Oncol 2:516-523, 1995
26. Haase GM, Wong KY, deLorimier AA, et al: Improvement in survival after excision of primary tumor in stage III neuroblastoma. J Pediatr Surg 24:194-200, 1989